…
Frenkel Topping Group Plc, together with its subsidiaries, provides professional and financial services in the personal injury and clinical negligence field in the United Kingdom. It operates through Financial Services, Costs Law, and Other Professional Services segments. The company offers independent financial advisory, discretionary fund management, and financial services; major trauma signposting, forensic accountancy, care and case management, and medico-legal reporting services; expert witness services; and costs management services. It also provides recruitment and legal costs services. Frenkel Topping Group Plc was founded in 1979 and is headquartered in Manchester, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | 4.15M | 3.19M | 2.42M | 2.69M | 1.55M |
| Minority interest | -0.24M | -0.25M | -0.20M | -0.14M | 0.16M |
| Net income | 2.79M | 1.66M | 1.65M | 2.34M | 1.05M |
| Selling general administrative | 9.71M | 8.80M | 8.23M | 4.77M | 3.32M |
| Gross profit | 13.52M | 13.87M | 11.13M | 9.02M | 5.54M |
| Reconciled depreciation | 0.85M | 0.72M | 0.57M | 0.33M | 0.32M |
| Ebit | 4.67M | 6.63M | 2.90M | 3.99M | 1.60M |
| Ebitda | 5.52M | 7.35M | 3.48M | 4.32M | 2.29M |
| Depreciation and amortization | 0.85M | 0.72M | 0.57M | 0.33M | 0.69M |
| Operating income | 4.67M | 5.07M | 2.90M | 3.99M | 1.60M |
| Other operating expenses | 32.73M | 27.74M | 21.95M | 14.53M | 8.25M |
| Interest expense | 0.74M | 0.38M | 0.48M | 0.32M | 0.08M |
| Tax provision | 1.12M | 1.29M | 0.57M | 0.22M | 0.38M |
| Interest income | 0.01M | 0.01M | 0.00M | 0.15M | 0.03M |
| Net interest income | -0.73M | -0.52M | -0.48M | -0.17M | -0.05M |
| Income tax expense | 1.12M | 1.29M | 0.57M | 0.22M | 0.38M |
| Total revenue | 37.40M | 32.81M | 24.85M | 18.37M | 10.19M |
| Total operating expenses | 9.71M | 8.80M | 8.23M | 5.18M | 3.60M |
| Cost of revenue | 23.02M | 18.94M | 13.72M | 9.35M | 4.65M |
| Total other income expense net | -0.52M | -1.88M | -0.48M | -1.29M | -0.05M |
| Net income from continuing ops | 3.03M | 1.91M | 1.85M | 2.48M | 1.17M |
| Net income applicable to common shares | - | - | 1.65M | 2.34M | 1.05M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 59.85M | 53.13M | 53.14M | 37.81M | 28.55M |
| Intangible assets | 4.95M | 4.95M | - | - | - |
| Other current assets | 8.96M | 0.90M | - | 10.27M | 4.85M |
| Total liab | 17.60M | 11.73M | 13.05M | 8.25M | 3.40M |
| Total stockholder equity | 41.94M | 41.06M | 39.81M | 29.36M | 24.99M |
| Other current liab | 5.85M | 5.07M | 0.32M | 2.34M | 0.48M |
| Common stock | 0.64M | 0.64M | 0.64M | 0.57M | 0.56M |
| Capital stock | 0.64M | 0.64M | 0.64M | 0.57M | 0.56M |
| Retained earnings | 20.48M | 13.13M | 12.30M | 11.72M | 11.11M |
| Other liab | - | - | 4.02M | 2.38M | 0.55M |
| Good will | 25.65M | 24.26M | - | 16.26M | 8.30M |
| Other assets | 59.85M | 53.13M | 0.16M | 0.56M | 0.22M |
| Cash | 3.14M | 2.42M | 4.99M | 8.62M | 12.00M |
| Total current liabilities | 7.32M | 9.11M | 8.44M | 5.87M | 2.55M |
| Current deferred revenue | - | 6.52M | - | -1.84M | -0.33M |
| Net debt | -3.14M | -1.35M | -3.96M | -8.23M | -11.55M |
| Short term debt | 0.61M | 0.49M | 0.44M | 0.17M | 0.15M |
| Short long term debt | 0.09M | 0.07M | - | - | - |
| Short long term debt total | 8.44M | 1.07M | 1.03M | 0.39M | 0.45M |
| Other stockholder equity | 20.58M | 20.57M | 26.88M | 17.08M | 13.32M |
| Property plant equipment | - | - | 2.83M | 1.99M | 1.95M |
| Total current assets | 25.70M | 20.78M | 20.57M | 19.00M | 18.08M |
| Net tangible assets | - | - | 10.23M | 13.11M | 16.69M |
| Short term investments | 0.11M | 0.11M | 0.10M | 0.11M | 1.23M |
| Net receivables | 13.49M | 17.35M | 10.66M | 6.35M | 4.51M |
| Long term debt | 6.90M | 0.00M | 0.04M | - | - |
| Accounts payable | 0.85M | 1.10M | 7.68M | 5.20M | 2.25M |
| Accumulated other comprehensive income | 0.25M | 6.71M | - | - | - |
| Common stock total equity | - | - | - | - | 0.56M |
| Treasury stock | - | - | - | - | -4.58M |
| Non currrent assets other | 0.10M | 0.15M | 0.16M | 0.13M | 0.10M |
| Non current assets total | 34.15M | 32.36M | 32.58M | 18.81M | 10.46M |
| Capital lease obligations | 1.45M | 1.00M | 1.00M | 0.39M | 0.45M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -5.12M | -3.81M | -11.75M | -4.45M | -0.43M |
| Change to liabilities | - | - | -0.10M | -0.16M | -0.07M |
| Total cashflows from investing activities | -5.12M | -3.81M | -11.75M | -4.45M | -1.00M |
| Net borrowings | 6.92M | 0.04M | -0.37M | -0.42M | -1.35M |
| Total cash from financing activities | 3.85M | -1.97M | 7.46M | 0.33M | 9.95M |
| Net income | 2.79M | 3.19M | 2.42M | 2.69M | 1.55M |
| Change in cash | 0.71M | -2.56M | -3.63M | -3.38M | 10.67M |
| Begin period cash flow | 2.42M | 4.99M | 8.62M | 12.00M | 1.33M |
| End period cash flow | 3.14M | 2.42M | 4.99M | 8.62M | 12.00M |
| Total cash from operating activities | 1.97M | 3.21M | 0.66M | 0.74M | 1.72M |
| Issuance of capital stock | 0.00M | 0.00M | 9.64M | 2.34M | 12.46M |
| Depreciation | 0.85M | 0.72M | 0.57M | 0.33M | 0.32M |
| Other cashflows from investing activities | - | - | - | - | -0.97M |
| Dividends paid | 1.90M | 1.45M | 1.77M | 1.56M | 1.13M |
| Change to account receivables | -2.55M | -2.74M | -2.21M | -1.71M | -0.06M |
| Sale purchase of stock | - | - | - | - | 12.46M |
| Other cashflows from financing activities | -1.17M | -0.04M | -0.41M | -0.22M | -0.19M |
| Change to netincome | - | - | 0.73M | -0.06M | 0.48M |
| Capital expenditures | 0.24M | 0.29M | 0.24M | 0.10M | 0.04M |
| Change in working capital | -2.35M | -2.12M | -2.30M | -1.87M | -0.13M |
| Stock based compensation | 0.23M | 0.50M | 0.48M | 0.29M | 0.22M |
| Other non cash items | 0.68M | 0.92M | -0.51M | 0.18M | 0.05M |
| Free cash flow | 1.75M | 2.92M | 0.42M | 0.64M | 1.68M |
Sector: Financial Services Industry: Asset Management
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MNTN Schiehallion Fund Ltd |
-0.01 0.46% |
2.18 | 0.05 | - | 4.35 | 1.25 | 5.65 | - |
| BHMU BH Macro Limited |
- -% |
4.29 | 0.09 | - | 39.01 | 0.71 | 6.47 | - |
| TFG Tetragon Financial Group Ltd |
0.15 1.00% |
15.10 | 0.02 | 7.04 | 1.16 | 0.31 | 2.06 | 6.56 |
| BPCR BioPharma Credit PLC |
0.00 0.41% |
0.98 | 0.09 | - | 6.73 | 0.91 | 7.95 | - |
Frenkel Topping Group Plc, together with its subsidiaries, provides professional and financial services in the personal injury and clinical negligence field in the United Kingdom. It operates through Financial Services, Costs Law, and Other Professional Services segments. The company offers independent financial advisory, discretionary fund management, and financial services; major trauma signposting, forensic accountancy, care and case management, and medico-legal reporting services; expert witness services; and costs management services. It also provides recruitment and legal costs services. Frenkel Topping Group Plc was founded in 1979 and is headquartered in Manchester, the United Kingdom.
Frenkel House, Manchester, United Kingdom, M50 2ZY
44 1618 868 000
416
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard C. Fraser | CEO & Exec. Director | NA |
| Ms. Elaine Nicola Cullen-Grant | Sec., CFO & Exec. Director | 1975 |
| Mr. Mark S. Holt | COO & Exec. Director | NA |
| Mr. Richard Petrie | Personal Injury Trust Devel. Consultant | NA |
| Mr. Richard Cullen Fraser | CEO & Executive Director | 1959 |
| Ms. Elaine Nicola Cullen-Grant | Secretary, CFO & Executive Director | 1975 |
| Mr. Mark Stuart Holt | COO, MD & Executive Director | 1976 |
| Ms. Denise Moore | Group Director of Compliance & Risk | NA |
| Ms. Tracey Atkinson | Director of People and Culture | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.